Cann Pharmaceutical Australia (CPA) was launched in 2016 - and was the first Australian company to obtain a joint venture with a licensed medicinal cannabis company in Israel - Cann Pharmaceutical Ltd of Israel. CPA was founded with the goal of breaking into the international market for the provision of medicinal cannabis treatments to children with epilepsy.​

In Australia, CPA's management, board of directors and advisors consist of proven business, academic and medical leaders with extensive histories of achievement in the medicinal cannabis sector, clinical research, and biotechnology.

Collectively, the team's breadth of experience ranges from advanced agribusiness technology, biotechnology, healthcare and the pharmaceutical sectors, plus proven entrepreneurial and business development in Australia and Israel.


CPA's certifications include the issuing of a License for Medicinal Cannabis Cultivation and Production from the Office of Drugs Control (ODC) in 2017, and the issuing of a License for Medicinal Cannabis Manufacturing in 2019.

Cann Pharmaceutical Australia
Level 1
The Realm
18 National Circuit
Barton ACT 2600
+61 2 6198 3253
  • LinkedIn
  • Facebook
  • Twitter
  • YouTube
Screen Shot 2021-02-08 at 3.34.34 pm cop
Screen Shot 2021-02-08 at 3.43.34 pm cop
The content on this website is not intended as a substitute for professional medical advice and/or as a recommendation and/or approval to use cannabis products, whether they are sold by the company or by another party.
© 2021 Cann Pharmaceutical Australia. All Rights Reserved.